Show simple item record

dc.contributor.authorPfeffer, Paul E.
dc.contributor.authorAli, Nasloon
dc.contributor.authorMurray, Ruth
dc.contributor.authorUlrik, Charlotte
dc.contributor.authorTran, Trung N.
dc.contributor.authorMaspero, Jorge
dc.contributor.authorPeters, Matthew
dc.contributor.authorChristoff, George C.
dc.contributor.authorSadatsafavi, Mohsen
dc.contributor.authorTorres-Duque, Carlos A.
dc.contributor.authorAltraja, Alan
dc.contributor.authorLehtimäki, Lauri
dc.contributor.authorPapadopoulos, Nikolaos G.
dc.contributor.authorSalvi, Sundeep
dc.contributor.authorCostello, Richard W.
dc.contributor.authorCushen, Breda
dc.contributor.authorHeffler, Enrico
dc.contributor.authorIwanaga, Takashi
dc.contributor.authorAl-Ahmad, Mona
dc.contributor.authorLarenas-Linnemann, Désirée
dc.contributor.authorKuna, Piotr
dc.contributor.authorFonseca, João A
dc.contributor.authorAl-Lehebi, Riyad
dc.contributor.authorRhee, Chin Kook
dc.contributor.authorPerez-de-Llano, Luis
dc.contributor.authorPerng Steve, Diahn-Warng
dc.contributor.authorMahboub, Bassam
dc.contributor.authorWang, Eileen
dc.contributor.authorGoh, Celine
dc.contributor.authorLyu, Juntao
dc.contributor.authorNewell, Anthony
dc.contributor.authorAlacqua, Marianna
dc.contributor.authorBelevskiy, Andrey S.
dc.contributor.authorBhutani, Mohit
dc.contributor.authorBjermer, Leif Hilding
dc.contributor.authorBjornsdottir, Unnur
dc.contributor.authorBourdin, Arnaud
dc.contributor.authorBulow, Anna von
dc.contributor.authorBusby, John
dc.contributor.authorCanonica, Giorgio Walter
dc.contributor.authorCosio, Borja G.
dc.contributor.authorDorscheid, Delbert R.
dc.contributor.authorMuñoz-Esquerre, Mariana
dc.contributor.authorFitzGerald, J. Mark
dc.contributor.authorGil, Esther Garcia
dc.contributor.authorGibson, Peter G.
dc.contributor.authorHeaney, Liam G.
dc.contributor.authorHew, Mark
dc.contributor.authorHilberg, Ole
dc.contributor.authorHoyte, Flavia
dc.contributor.authorJackson, David J.
dc.contributor.authorKoh, Mariko Siyue
dc.contributor.authorKo, Hsin-Kuo Bruce
dc.contributor.authorLee, Jae Ha
dc.contributor.authorLehmann, Sverre
dc.contributor.authorChaves Loureiro, Cláudia
dc.contributor.authorLúðvíksdóttir, Dóra
dc.contributor.authorMenzies-Gow, Andrew N.
dc.contributor.authorMitchell, Patrick
dc.contributor.authorPapaioannou, Andriana I.
dc.contributor.authorPopov, Todor A.
dc.contributor.authorPorsbjerg, Celeste M.
dc.contributor.authorSalameh, Laila
dc.contributor.authorSirena, Concetta
dc.contributor.authorTaillé, Camille
dc.contributor.authorTaube, Christian
dc.contributor.authorTohda, Yuji
dc.contributor.authorWechsler, Michael E.
dc.contributor.authorPrice, David B.
dc.date.accessioned2023-11-15T10:50:54Z
dc.date.available2023-11-15T10:50:54Z
dc.date.created2023-06-28T11:03:27Z
dc.date.issued2023
dc.identifier.issn0105-4538
dc.identifier.urihttps://hdl.handle.net/11250/3102692
dc.description.abstractBackground: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). Conclusions: In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleComparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for bothen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 the authorsen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1111/all.15711
dc.identifier.cristin2159006
dc.source.journalAllergy. European Journal of Allergy and Clinical Immunologyen_US
dc.source.pagenumber1934-1948en_US
dc.identifier.citationAllergy. European Journal of Allergy and Clinical Immunology. 2023, 78 (7), 1934-1948.en_US
dc.source.volume78en_US
dc.source.issue7en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal